Veru
VERU2.2400.90% ( +0.020 )
Veru (VERU)
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acu...
- Open
- 2.260
- High
- 2.270
- Low
- 2.169
- Prev. Close
- 2.220
- Volume
- 153.70K
- Turnover
- 341.94K
- Avg Price
- 2.225
- Bid/Ask Ratio
- --
- Amplitude
- 4.55%
- 52wk High
- 7.330
- Volume Ratio
- 0.57
- Turnover Ratio
- 1.14%
Veru Analyst Rating
View MoreForecast & Rating
Jun 4, 2026Price forecast
$24.50993.75%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 30 at 07:33 AM
Veru CEO Steiner joins Canaccord Genuity Growth Investors Conference fireside chat
- Global Report · Jul 28 at 04:12 AM
Cross-Sector M&A Accelerates as U.S. Mid-Caps Push for Restructuring
- Unusual Whales · Jul 27 at 07:12 AM
Veru completes Phase 2b PLATEAU trial enrolling 250 patients for weight loss with Enobosarm and Semaglutide combo.
- StockTitan · Jul 26 at 11:10 PM
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | VERU Stock News
- PUBT · Jul 7 at 07:36 AM
Veru says press release available on 2026 Obesity & Weight Loss Drug Development Summit presentation
- PUBT · Jul 2 at 03:09 PM
Veru enters at-the-market equity sales agreement for up to $21.8 million stock offering
